| 8. | Employee
future benefits |
The
change in the Company’s employee future benefit obligations is summarized as follows:
Summary
of net defined benefit liability asset
| | |
benefit
plans | | |
benefit
plans | | |
Total | | |
Total | |
| | |
Three
months ended March
31, 2026 | | |
Year
ended December 31, 2025 | |
| | |
Pension | | |
Other | | |
| | |
| |
| | |
benefit
plans | | |
benefit
plans | | |
Total | | |
Total | |
| | |
$ | | |
$ | | |
$ | | |
$ | |
| Change in plan liabilities | |
| | | |
| | | |
| | | |
| | |
| Balances – Beginning of the period | |
| 22,197 | | |
| 39 | | |
| 22,236 | | |
| 22,403 | |
| Current service cost | |
| - | | |
| - | | |
| - | | |
| 16 | |
| Interest cost | |
| - | | |
| - | | |
| - | | |
| 825 | |
| Actuarial loss (gain) from changes in financial
assumptions | |
| - | | |
| - | | |
| - | | |
| (1,916 | ) |
| Benefits paid | |
| - | | |
| - | | |
| - | | |
| (896 | ) |
| Impact of foreign exchange rate changes | |
| - | | |
| - | | |
| - | | |
| 1,804 | |
| Deconsolidation of German
subsidiaries | |
| (22,197 | ) | |
| (39 | ) | |
| (22,236 | ) | |
| - | |
| Balances – End
of the period | |
| - | | |
| - | | |
| - | | |
| 22,236 | |
| | |
| | | |
| | | |
| | | |
| | |
| Change in plan assets | |
| | | |
| | | |
| | | |
| | |
| Balances – Beginning of the period | |
| 11,251 | | |
| - | | |
| 11,251 | | |
| 10,669 | |
| Interest income from plan assets | |
| - | | |
| - | | |
| - | | |
| 396 | |
| Employer contributions | |
| - | | |
| - | | |
| - | | |
| 32 | |
| Employee contributions | |
| - | | |
| - | | |
| - | | |
| 7 | |
| Benefits paid | |
| - | | |
| - | | |
| - | | |
| (311 | ) |
| Remeasurement of plan assets | |
| - | | |
| - | | |
| - | | |
| 47 | |
| Unrecognized Asset due to Asset Ceiling | |
| - | | |
| - | | |
| - | | |
| (631 | ) |
| Impact of foreign exchange rate changes | |
| - | | |
| - | | |
| - | | |
| 1,042 | |
| Deconsolidation of German
subsidiaries | |
| (11,251 | ) | |
| - | | |
| (11,251 | ) | |
| - | |
| Balances – End
of the period | |
| - | | |
| - | | |
| - | | |
| 11,251 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net liability of the unfunded plans | |
| - | | |
| - | | |
| - | | |
| 10,984 | |
| Net liability of the funded
plans | |
| - | | |
| - | | |
| - | | |
| - | |
| Net
amount recognized as Employee future benefits | |
| - | | |
| - | | |
| - | | |
| 10,984 | |
| | |
| | | |
| | | |
| | | |
| | |
| Amounts recognized: | |
| | | |
| | | |
| | | |
| | |
| In net loss | |
| - | | |
| - | | |
| - | | |
| 435 | |
| Actuarial gain (loss) on defined benefit plans
in other comprehensive loss | |
| - | | |
| - | | |
| - | | |
| 1,960 | |
The
calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the
rate of the pension benefit increase.
COSCIENS Biopharma
Inc.
Notes to the
Condensed Interim Consolidated Financial Statements
As
of March 31, 2026, and for the three months ended March 31, 2026, and 2025
(In thousands
of US dollars, except share and per share data and as otherwise noted)
(Unaudited)
|